| Literature DB >> 34129228 |
Michael Spartalis1,2, Kenzaburo Nakajima3, David Zweiker3, Eleftherios Spartalis4, Dimitrios C Iliopoulos4, Gerasimos Siasos5.
Abstract
Despite constant breakthroughs in heart failure (HF) therapy, the population of HF patients resume to grow and is linked to increased mortality and morbidity. Ventricular arrhythmias (VA) are one of the leading causes of mortality in HF subjects. Implantable cardioverter-defibrillators (ICDs) are currently the gold standard in treatment, preventing arrhythmic sudden cardiac death (SCD) episodes. However, the death rates related to HF remain elevated, as not all HF subjects benefit equally. Cardiac resynchronization therapy (CRT) has emerged as a novel approach for HF patients. These devices have been thoroughly investigated in major randomized controlled studies but continue to be underutilized in various countries. This review discusses the use of ICD in HF populations on top of treatments.Entities:
Keywords: Cardiac resynchronization therapy; Heart failure; Implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular arrhythmias
Year: 2021 PMID: 34129228 DOI: 10.1007/s40119-021-00225-7
Source DB: PubMed Journal: Cardiol Ther ISSN: 2193-6544